Manufacturer's drug interaction and postmarketing adverse event data: What are appropriate uses?

Drug Safety

Volumn 24, Issue 9, 2001, Pages 637-643

  Kraft, W K ^a   Waldman, S A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DECISION MAKING; DRUG MANUFACTURE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; GOVERNMENT; LEGAL LIABILITY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REGULATORY MECHANISM; RISK BENEFIT ANALYSIS;

EID: 0034879223     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200124090-00001     Document Type: Article

References (34)

1. Mechanism of the cardiotoxic actions of terfenadine
2. Torsade de pointes occurring in association with terfenadine use
3. The contribution of P-glycoprotein to pharmacokinetic drug interactions
4. Assessment of the quality and quantity of drug interaction studies in recent NDA submissions: Study design and data analysis issues
5. FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug interactions: Impact on labeling
6. Adverse drug reactions: A review
7. Adverse drug reactions: Physicians opinions versus a causality assessment methods
8. Patients as a direct source of information on adverse drug reactions
9. The role of the WHO Programme on International Drug Monitoring Coordinating Worldwide Drug Safety Efforts
10. MedWatch: FDA's medical products reporting program
11. Thrombotic Thrombocytopenic Purpura and Clopidogrel: A need for new approaches to drug safety
12. Pharmacovigilance in perspective
13. Freedom of information, when it suits
14. Freedom of information
15. Managing the risk from medical product use: Creating a risk management framework
16. Intellectual property, drug licensing, freedom of information and public health
17. Study information submitted by drug companies to licensing authorities
18. The Food and Drug Administration's regulation of drug labeling, advertising, and promotion: Looking back and looking ahead
19. Adverse drug reactions: A review of relevant factors
20. Adverse drug events and the freedom of information act: An apple in eden
21. Postmarketing surveillance and adverse drug reactions: Current perspectives and future needs
22. Meta-analysis and epidemiologic studies in drug development and post marketing surveillance
23. Japan plans improved monitoring of new drugs
24. Shattuck lecture - Evaluating the health risks of breast implants: The interplay of medical science, the law, and public opinion
25. Silicone breast implants and the risk of connective-tissue diseases and symptoms
26. Experience of a scientific panel formed to advise the Federal Judiciary on silicone breast implants
27. Pediatricians concerned by lack of context for MedWatch data